- Home
- OI vs OCS Comparison
OI vs OCS Comparison
Compare OI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | OCS |
|---|---|---|
| Founded | 1903 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | OI | OCS |
|---|---|---|
| Price | $9.08 | $11.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $15.29 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | N/A |
| Revenue This Year | $2.77 | $466.06 |
| Revenue Next Year | $1.88 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.75 | $10.52 |
| 52 Week High | $16.91 | $34.48 |
Technical Indicators
Market Signals| Indicator | OI | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 24.27 |
| Support Level | $7.96 | $10.52 |
| Resistance Level | $9.36 | $21.82 |
| Average True Range (ATR) | 0.42 | 1.68 |
| MACD | 0.15 | -0.24 |
| Stochastic Oscillator | 67.10 | 4.24 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.